REVO

- Expanding clinical use in public healthcare institutions, with world-first and high-complexity surgical achievements

- Contributing to the global expansion of K-surgical robotics through physician training and international collaboration

meerecompany (CEO Joon Koo Kim) announced on the 25th that Korea Cancer Center Hospital, under the Korea Institute of Radiological and Medical Sciences (KIRAMS), has reached 500 robotic surgeries using “Revo-i” and held a commemorative event on March 24.

The event was organized to share clinical outcomes accumulated through the use of a domestically developed surgical robot in a public healthcare institution, while also expanding collaboration among robotic surgery users. It also highlighted how national R&D has been successfully translated into real-world clinical practice, with key stakeholders in attendance underscoring the significance of the milestone.

Approximately 140 attendees from both organizations participated in the event, including Ju Young Lee, Member of the National Assembly (Health and Welfare Committee, Reform Party); Jin Kyung Lee, President of KIRAMS; Dong Ho Kim, President of Korea Cancer Center Hospital; Kang Hyon Song, Director of the Robotic Surgery Center at Korea Cancer Center Hospital; Seung Pil Jeong, President of Dongnam Institute of Radiological and Medical Sciences; Dong Hwan Kim, President of Seoul National University of Science and Technology; Joon Koo Kim, CEO of meerecompany; and Ho Kun Lee, Executive Vice President and Head of the Surgical Robot Division at meerecompany.

The program centered on academic sessions sharing real-world clinical cases and research experiences using a domestically developed surgical robot. The first session, titled the “KIRAMS Korea Cancer Center Hospital Robotic Surgery Symposium,” commemorated the achievement of 500 cases at a single institution and reviewed accumulated clinical outcomes. Presentations focused on cancer treatment results using Revo-i, delivered by Kang Hyon Song, Head of the Urology Department; Myung Chul Lee, Head of the Otolaryngology Department; and Ji Sik Kang, Head of the Obstetrics and Gynecology Department.

The second session, “Meet the Revo Surgeons,” featured case studies from leading domestic hospitals. Professor Hyoung-Il Kim from the Department of Surgery at Severance Hospital, and Jeong Hwan Son, Head of the Urology Department at Bundang Jesaeng Hospital, shared their institutional experiences and clinical data using the Revo-i system, while discussing future directions and the potential for expanding clinical adoption of domestically developed surgical robots.

Robotic surgery enables more precise manipulation of surgical sites through high-resolution imaging and advanced robotic instruments, supporting minimally invasive procedures that can reduce bleeding, pain, and recovery time. Korea Cancer Center Hospital has steadily expanded its clinical application of Revo-i since its initial adoption, accumulating a broad range of surgical experience. Based on this experience, the hospital’s medical team has achieved several pioneering surgical milestones using Revo-i.

Myung Chul Lee, Head of the Otolaryngology Department, performed the world’s first transoral robotic surgery using Revo-i and also successfully conducted the first parathyroidectomy with the system. In addition, Kang Hyun Song, Director of the Robotic Surgery Center, successfully carried out a high-complexity simultaneous surgery last year, removing both prostate and kidney cancers in a 74-year-old patient.

Meanwhile, Korea Cancer Center Hospital and meerecompany continue to actively collaborate on robotic surgery training and clinical exchange programs for both domestic and international medical professionals. In June last year, the two institutions signed a Memorandum of Agreement (MOA) to operate training programs for domestic and international clinicians.

Under this framework, international physicians visiting Korea participate in surgical observation and advisory sessions to gain hands-on experience with the Revo-i system. In addition, medical teams are dispatched to countries with limited healthcare infrastructure to share surgical techniques, with Algeria serving as a representative example.

Ho Kun Lee, executive vice president and head of the Surgical Robot Division at meerecompany, commented, “We sincerely congratulate Korea Cancer Center Hospital on achieving 500 robotic surgeries with Revo-i. The steady accumulation of clinical experience with a domestically developed surgical robot in a public healthcare institution is a highly meaningful achievement.”

He added, “We hope this milestone will serve as a catalyst for expanding the adoption of domestically developed medical devices across other public healthcare institutions in the future.”